



NOVACYT ANNOUNCES INITIATION OF COVERAGE BY INVEST SECURITIES

Paris, France and Cambridge, UK –19 January, 2016 – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that Invest Securities, an independent investment banking and advisory group, based in Paris, has initiated research coverage of Novacyt.

Today's appointment represents another step forward as the Company increases its scale and international profile.

- Ends -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NOVAprep® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts:

International

Brett Pollard / Victoria Foster Mitchell
FTI Consulting
+44 (0)20 3727 1000
Brett.Pollard@fticonsulting.com / Victoria.FosterMitchell@fticonsulting.com

France

Arnaud de Cheffontaines / Astrid Villette
FTI Consulting
+33 1 47 03 69 47 / +33 1 47 03 69 51
Arnaud.deCheffontaines@fticonsulting.com / Astrid.Villette@fticonsulting.com

NOVACYT

Graham Mullis
Chief Executive Officer
+44 7901 514121
Graham.mullis@novacyt.co.uk